Several key issues including standardisation and validation of ctDNA response criteria for predicting clinical outcomes in oncology still need to be addressed
Studies investigate the discriminatory capacity of existing prognostic scales and the factors associated with survival to help select patients who may benefit from participation in early phase trials
Research is ongoing to revisit the classic neoantigen approach that may better interpret the complexity of the immune system
The 2024 TAT Honorary Awardee Prof. Funda Meric-Bernstam discusses progress made and how to overcome current obstacles in the field
A phase II trial reports a longer recurrence-free and distant-metastasis free survival with the combination of mRNA and pembrolizumab.
A study describes an additivity model that can be used to predict the likelihood of success or failure of combination therapies in phase III trials
Evidence is compelling, but utility may depend on the clinical context
Well-designed real-world observational studies are hypothesis-generating and impact therapeutic decisions
Addressing cost and affordability issues is now key to increasing the use of this approach in the clinical setting in Asia
Several ESMO initiatives highlight the need for closing the gap between fast cancer research and a lack of accessibility to treatments in the real world
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.